向瘤微环境衍生的NRG1-HER2/3信号与诺库图祖马布恢复了对PTEN野生型前列腺癌中AR抑制的敏感性
Brian M Shinder1, Young Sun Lee2, Ninghui Mao2
1Johns Hopkins University, Baltimore, MD, United States.
Molecular cancer therapeutics
|December 11, 2025
概括
来自癌细胞的神经调节素1 (NRG1) 在PTEN野生型前列腺癌中驱动对雄激素受体 (AR) 治疗的耐药性. 向NRG1使用泽诺库图祖马布可以恢复这些瘤对AR抑制剂的敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 对雄激素受体 (AR) 向疗法的获得性耐药性是前列腺癌治疗中的一个主要临床挑战.
- 癌症相关纤维细胞 (CAFs) 所分泌的神经调节素1 (NRG1) 曾经被证明可以通过HER3-AKT信号传递促进抗雄激素耐药性.
- 了解驱动NRG1介导耐药性的特定分子背景对于开发有效的治疗策略至关重要.
研究的目的:
- 研究NRG1诱导的PI3K信号驱动AR抑制剂耐药性的分子背景.
- 评估向HER2/3二分化是否可以恢复对AR抑制的敏感性.
- 评估泽诺库图祖马布在克服前列腺癌中NRG1介导的抗雄激素耐药性的疗效.
主要方法:
- 来自接受或不接受新辅助激素治疗的患者的前列腺切除样本的免疫组织化学分析.
- 用重组NRG1或CAF受条件介质刺激PTEN野生型和PTEN缺乏的前列腺癌细胞.
- 用以治疗前列腺癌细胞和瘤,使用针对HER2/3的双特异性抗体 - - 泽诺库图祖马布,与AR抑制剂结合治疗.
主要成果:
- 在AR抑制后,NRG1显著上调,无论PTEN状态如何.
- 只有在PTEN野生型前列腺癌细胞中,NRG1诱导抗AR抑制,而不是在PTEN缺乏细胞中.
- 泽诺库图祖马布在PTEN野生型瘤中恢复了对AR向治疗的敏感性,但在PTEN缺乏的环境中没有恢复.
结论:
- 瘤微环境 (TME) 衍生的NRG1在调解抗AR抑制的抵抗方面发挥着关键作用,特别是在PTEN野生型前列腺癌中.
- 向NRG1使用泽诺库图祖马布是一种有前途的策略,可以在PTEN野生型前列腺癌中克服对雄激素阻塞的抵抗.
- 在AR抑制剂耐药性的背景下,PTEN状态是对NRG1向疗法的反应的关键决定因素.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:17The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K